Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Evaluating the Effects of Varenicline on Smoking Lapse in Smokers With and Without Schizophrenia: Implications for Treatment

NCT01850953 is registered in ClinicalTrials.gov with Centre for Addiction and Mental Health as lead sponsor.

NCT NCT01850953
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01850953 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Evaluating the Effects of Varenicline on Smoking Lapse in Smokers With and Without Schizophrenia: Implications for Treatment
Lead sponsor
Centre for Addiction and Mental Health
Phase
Phase 4
Overall status
Completed
Start date
June 30, 2013
Completion date
May 31, 2015
Enrollment
28 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

craving, schizophrenia, smoking